Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05787496 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
A Phase 1 study, sponsored by NextCure.
- Terminated
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT05787496 is a Phase 1 study that was terminated before completion, run by NextCure. The registered enrollment target is 28 participants.
The verdict
NCT05787496, a Phase 1 study, was terminated before completion, sponsored by NextCure.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
Interventions
- DRUG NC525
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2023-02-28 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05787496
The ClinicalTrials.gov registry entry for NCT05787496 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NextCure, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NC525 is the first listed.
NCT05787496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05787496 about?
NCT05787496 is a clinical study titled "A Safety, Tolerability and Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms". This is an open-label, non-randomized, Phase 1 study to determine the safety and tolerability of NC525. This study will also assess the clinical benefit in subjects with advanced myeloid neoplasms.
What is the current status of trial NCT05787496?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2023-02-28. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05787496?
The interventions under investigation include: NC525 (DRUG).
Who is sponsoring clinical trial NCT05787496?
This trial is sponsored by NextCure, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.